InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
7
T+90 hit rate
44%
T+90 mean return
+2.8%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by SIEGAL JONATHAN, Directeur Comptable. Director active across 1 company, notably Vericel Corp. Cumulatively, 16 filings have been recorded. Breakdown: 0 buy · 7 sells. Total volume traded: €353k. Activity tracked since 30 September 2022. The latest transaction was filed on 6 May 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations16 total
3,433 shares@ US$38.000.0066% mcap50.0% of flowCommon StockSEC:0001140361-26-020030
3,433 shares@ US$38.000.0066% mcap50.0% of flowCommon StockSEC:0001140361-26-020030:0
1,875 shares0Common StockSEC:0001140361-25-006081:0
2,500 shares0Common StockSEC:0001140361-25-005257:0
1,092 shares@ US$48.808.8% of flowCommon StockSEC:0001140361-25-003567:0
3,908 shares@ US$48.8031.1% of flowCommon StockSEC:0001140361-25-002441:0
937 shares0Common StockSEC:0001140361-24-042559:0
545 shares@ US$45.003.9% of flowCommon StockSEC:0001140361-24-032762:0
1,634 shares@ US$45.0011.5% of flowCommon StockSEC:0001140361-24-012610:0
2,500 shares0Common StockSEC:0001140361-24-009029:0
662 shares@ US$37.6953.9% of flowCommon StockSEC:0001140361-23-053858:0
938 shares0Common StockSEC:0001140361-23-046932:0
419 shares0Common StockSEC:0001127602-23-006604:0
330 shares@ US$31.001.6% of flowCommon StockSEC:0001127602-23-003302:0
331 shares@ US$25.471.5% of flowCommon StockSEC:0001127602-22-024068:0
937 shares0Common StockSEC:0001127602-22-023522:0
16 of 16 declarations
About SIEGAL JONATHAN
Jonathan Siegal is the Principal Accounting Officer at Vericel Corp. In this role, he oversees accounting operations and ensures compliance with the company's financial statements. Vericel Corp. specializes in developing regenerative medicine products. Mr. Siegal plays a key role in analyzing financial performance and preparing financial reports.
